BioSpace News Archive

KromaTiD and Noble Life Sciences have entered a distribution and OEM agreement for products and services that enable a complete analysis of novel cell and gene therapies’ potential toxicity prior to an Investigational New Drug application.

NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products.

Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced that Anthem Blue Cross and Blue Shield has established favorable coverage for the Intracept® Procedure.

Scilex Holding Company provides notice to all record holders and beneficial owners of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. to Sorrento equity holders of record as of January 9, 2023.

Centinel Spine®, LLC announced that more than 250,000 prodisc devices have been implanted worldwide.* The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany.

Akura Medical, a Shifamed portfolio company focused on a differentiated approach to effectively address the major challenges of venous thromboembolism (VTE), announced today the closing of its $35M Series B financing.

ZeptoMetrix® is pleased to announce it has been awarded an IVDR Quality Management System certificate from British Standards Institution BSI, NB 2797, one of the notified bodies under the new EU In Vitro Diagnostics Regulation.

SurGenTec, a privately held medical device company focusing on spine and orthopedic technologies, proudly announces FDA clearance for TiLink-P, a first-of-its-kind, minimally-invasive implant that offers hope for individuals suffering from chronic sacroiliac (SI) joint pain.

Neuronetics, Inc., a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that it has drawn down the remaining $22.5 million from its credit facility with SLR Capital Partners, LLC.

Cosette Pharma announced that it has entered into an agreement with Mark Cuban Cost Plus Drug Company, PBC to offer CLOMID® 50mg tablets at a low cash price via the Cost Plus Drugs online pharmacy.